Advanced disease and CD8+ TEMRA cells predict severe infections in multiple myeloma
We developed a straightforward risk score that considers the relevance of T cell fitness in MGUS and NDMM patients and can help physicians to identify patients at risk of infection, thus enabling the implementation of timely and individualized prevention strategies.
Authors
- David R. Busch (ORCID: https://orcid.org/0000-0002-9488-944X)
- Il‐Kang Na (ORCID: https://orcid.org/0000-0001-9902-5424)
- Marco Frentsch (ORCID: https://orcid.org/0000-0003-3200-210X)
- Lars Bullinger (ORCID: https://orcid.org/0000-0002-5890-5510)
- Igor Wolfgang Blau (ORCID: https://orcid.org/0000-0003-1416-819X)
- Phillip Schiele (ORCID: https://orcid.org/0000-0002-2342-3597)
- Eva Tranter (ORCID: https://orcid.org/0000-0001-7752-4126)
- Axel Nogai
- Christian Meisel
- Clarissa Heck (ORCID: https://orcid.org/0009-0006-6642-5142)
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Humboldt-Universität zu Berlin (DE)
- Vivantes Klinikum (DE)
- Praxis für Hämatologie und Onkologie (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1532645
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Baxalta
- Octapharma
- Berlin Institute of Health